This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: Université´ D'aix-Marseille, Assitance Publique Hôpitaux De Marseille, Centre National De La Recherche Scientifique. Active years: 2015-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 237 
1 out of 1 
1 out of 5,383 
Years Active: 2015-2016
Title: Pierre-Marie Martin: Innovator in Antibody Research
Introduction
Pierre-Marie Martin is a notable inventor based in Marseille, France. He has made significant contributions to the field of antibody research, particularly in relation to adrenomedullin and its receptors. With a total of 2 patents, his work has implications for drug development and therapeutic applications.
Latest Patents
Martin's latest patents include innovative discoveries in the realm of antibodies. The first patent focuses on antibodies that bind to adrenomedullin and to proteins forming adrenomedullin receptors, detailing their potential uses as drugs. The second patent emphasizes antibodies binding to the proteins forming adrenomedullin receptors and their applications as a drug. These inventions highlight his commitment to advancing medical science through targeted therapies.
Career Highlights
Throughout his career, Pierre-Marie Martin has been associated with prestigious institutions such as Université d'Aix-Marseille and the Centre National de la Recherche Scientifique. His work in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research.
Collaborations
Some of Martin's notable coworkers include Kamel Mabrouk and L'Houcine Ouafik. Their collaborative efforts have further enriched the research landscape in which Martin operates.
Conclusion
Pierre-Marie Martin's contributions to antibody research and his innovative patents underscore his role as a significant figure in the scientific community. His work continues to pave the way for advancements in drug development and therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile